>>Description of the research protocol "LaCa Study"

Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial (LACA)
Phase II study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Nephrologie clinique
Brugmann identifier : LaCa Study
EudraCT identifier : 2014-000308-82


Involved department : Nephrology-dialysis
Principal investigator : Pozdzik
Sponsor : UZ
Contact : Clinical Research Unit

>This protocol was approved by the UZ Brussel ethics committee.